Clinical Trials · NCT01438073
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 96
- Start date
- Sep 2011
- Locations
- 1 site, United States
- Primary endpoint
- Average difference in Luteinizing Hormone (LH) concentration at the beginning and end of kisspeptin infusion